Selling or licensing your IP or drug development work to a pharmaceutical company is one way of progressing a promising new candidate from the lab to the market. This webinar aims to give you the perspective from the other side of the table so you can be better prepared when entering into negotiations with Pharma.
- Current state of play in Pharma transactions – an overview
- Understanding Pharma motivators
- Types and stage of deals
- The role of the deal champion
- Finding the win-win outcome
- The integration process – beyond the deal
Rob Crombie is currently the VIC/TAS State Lead for i4 Connect delivering the Federal Governments Accelerating Commercialisation programme through his role as Managing Director of Concept2Clinic Consulting, a specialist professional services company looking to turn smart innovation into commercial ventures. Rob’s has had previous roles as CEO of VC backed QUE Oncology Incorporated as well as the founding CEO of ASX-listed Prescient Therapeutics, in-licensing early stage drug candidates from Universities including Yale and Emory University and building value by advancing these assets through company sponsored clinical trials. Rob also played a key role as Head of Melbourne Operations at Arana Therapeutics taking the company from CSIRO spin-out through an IPO and merger to Arana’s final $318M upfront cash sale to US-based Cephalon Incorporated.
PD+ streams: MedTech and Life Sciences | Commercialisation of Research
